July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Nicotinamide protects against PVR by preventing RPE cells to undergo EMT
Author Affiliations & Notes
  • Marie Fernandes
    Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
    The Black Family Stem Cell Institute, New York, New York, United States
  • Lauren Schiff
    Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
    The Black Family Stem Cell Institute, New York, New York, United States
  • Tomasz Swigut
    Stanford University, Stanford, California, United States
  • Nathan Boles
    Neural Stem Cell Institute, Rensselaer , New York, United States
  • Rajini Srinivasan
    Stanford University, Stanford, California, United States
  • Alvaro Rada-Iglesias
    University of Cologne, Cologne, Germany
    Center for Molecular Medicine Cologne, Cologne, Germany
  • Qingjie Wang
    Neural Stem Cell Institute, Rensselaer , New York, United States
  • Janmeet Saini
    Neural Stem Cell Institute, Rensselaer , New York, United States
  • Tom Kiehl
    Neural Stem Cell Institute, Rensselaer , New York, United States
  • Jeffrey Stern
    Neural Stem Cell Institute, Rensselaer , New York, United States
  • Joanna Wysocka
    Stanford University, Stanford, California, United States
    4Howard Hughes Medical Institute, Stanford, California, United States
  • Sally Temple
    Neural Stem Cell Institute, Rensselaer , New York, United States
  • Timothy A Blenkinsop
    Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York, United States
    The Black Family Stem Cell Institute, New York, New York, United States
  • Footnotes
    Commercial Relationships   Marie Fernandes, None; Lauren Schiff, None; Tomasz Swigut, None; Nathan Boles, None; Rajini Srinivasan, None; Alvaro Rada-Iglesias, None; Qingjie Wang, None; Janmeet Saini, None; Tom Kiehl, None; Jeffrey Stern, None; Joanna Wysocka, None; Sally Temple, None; Timothy Blenkinsop, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2477. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marie Fernandes, Lauren Schiff, Tomasz Swigut, Nathan Boles, Rajini Srinivasan, Alvaro Rada-Iglesias, Qingjie Wang, Janmeet Saini, Tom Kiehl, Jeffrey Stern, Joanna Wysocka, Sally Temple, Timothy A Blenkinsop; Nicotinamide protects against PVR by preventing RPE cells to undergo EMT. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2477.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In proliferative vitreoretinopathy (PVR), the retinal pigmented epithelium (RPE) undergoes an epithelial to mesenchymal transition (EMT) and becomes contractile leading to retina detachment and vision loss. EMT is associated with RPE exposure to cytokines. We model this using primary adult human RPE (ahRPE) to study the mechanisms of RPE transformation. We compare in vitro transformed RPE to patient-dissected PVR samples by RNA seq and identify networks enriched in both. We then test the efficacy of inhibitors to proteins in these shared networks in their ability to prevent and or reverse the RPE transformation into contractile membranes.

Methods : ahRPE are isolated from human donor globes obtained from eye banks. Passage 0 RPE monolayers are replated and treated 5 days with 10ng/ml TGFb1 or TNFα alone, or TGFb1/TNFa. RNA is reverse transcribed and cDNA is used for sequencing with the Illumina HiSeq. Reads are analyzed with tophat v2.0.14 to the gencode 23 transcriptome model and htseq. Differential analysis is performed with DESeq2. Gene networks enriched in RPE treated with TGFb1/TNFa are analyzed by Enrichr to identify pathways. Nicotinamide (NIC) was identified as a potential inhibitor and used to treat RPE that undergoes EMT induced by TGFb1/TNFa. RPE cells are subjected to immunofluorescence (IF), imaged by confocal, time-lapse microscopy and their RNAs subjected to qPCR.

Results : Primary ahRPE treated with TGFb1/TNFa undergo EMT and create contractile membranes resembling those observed in patients with PVR, as shown by gene and protein expression data. RNA seq comparison between patient PVR membranes, native RPE and contractile RPE obtained in vitro showed that datasets from in vitro PVR membranes clustered with patient specimens and away from native RPE. This suggests that our in vitro model mimics in vivo PVR. When cultured in the presence of NIC, RPE retained their native phenotype (tight junctions, expression of RPE markers) whereas without NIC they express EMT markers. We also found that NIC can prevent RPE to develop contractile membranes when exposed to TGFb1/TNFa.

Conclusions : We can model PVR and recapitulate molecular changes similar to those observed in patient dissected PVR membranes. NIC prevents RPE to undergo EMT and in vitro contractile membranes formation suggesting that NIC is a promising therapeutic agent to treat patients with PVR.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×